What it sells
Accelerating clinical trials and reducing delays
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinical operations/development leads at sponsors; proposal and bid teams at CROs.
Trigger: what makes them buy now?
Wanting to run a trial with a leaner team and reach first participant faster (sponsors); needing to price bids on precedent and defend change orders (CROs).
Workflow: what inputs become what output?
Turn a trial brief into a versioned "living blueprint": feasibility and strategy, design and Schedule of Assessments, risk register, budget or priced bid, protocol and country packs, compliance review; budget moves automatically when design changes.
Distribution: how it reaches customers
Demo-led ("Book a demo"); separate sponsor and CRO pages; ISO 27001 certified, deployed in the customer region.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-07 | — | €3.8M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.